We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HighTide Therapeutics

News List

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress PharmaSources
June 05, 2024
Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) PharmaSources
January 12, 2023
HighTide Therapeutics Inc. announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations PharmaSources.com
January 05, 2023
HighTide Therapeutics announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund.
HighTide Therapeutics Receives Fast Track Designation for HTD1801 americanpharmaceuticalreview
September 29, 2018
HighTide Therapeutics announced the FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholangitis (PSC).